search
Back to results

The Effect of SOD Enzyme on Frailty and HRQOL Among Indonesian Pre-frail Elderly: A Double Blind Randomized Controlled Trial

Primary Purpose

Pre-frail Elderly

Status
Unknown status
Phase
Phase 4
Locations
Indonesia
Study Type
Interventional
Intervention
SOD+Gliadin Capsule
Placebo
Sponsored by
Indonesia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pre-frail Elderly focused on measuring Elderly, pre-frail, SOD

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Elderly aged 60 years or more with pre-frail condition
  • Patients with SOD enzyme deficiency
  • Willing to participate

Exclusion Criteria:

  • Patients with cognitive function impairment (AMT score < 8)
  • Patients with depression (Geriatric depression scale score >= 10)
  • Patients with history of cirrhotic hepatic disease or severe hepatic disease
  • Patients with kidney function impairment
  • Patients with gluten allergy and derivative products
  • Patients consume other antioxidant and omega-3 supplement

Sites / Locations

  • Cipto Mangunkusumo National HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Intervention

Placebo

Arm Description

SOD+Gliadin capsule is given in a dosage of 250 mg twice a day, for 24 weeks.

Placebo capsule is given in a dosage of 250 mg twice a day, for 24 weeks.

Outcomes

Primary Outcome Measures

Frailty status
Measured by FI-40 item questionnaire.

Secondary Outcome Measures

Health related quality of life
Measured by EQ5D questionnaire.
Anti-oxidant serum status
Measured by erythrocyte antioxidant enzymes activity, i.e. superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX).
Morbidity
Measured by Cumulative Illness Rating Score (CIRS).
Hospitalization
Observed hospitalization event during the study

Full Information

First Posted
April 12, 2016
Last Updated
May 27, 2016
Sponsor
Indonesia University
search

1. Study Identification

Unique Protocol Identification Number
NCT02753582
Brief Title
The Effect of SOD Enzyme on Frailty and HRQOL Among Indonesian Pre-frail Elderly: A Double Blind Randomized Controlled Trial
Official Title
The Effect of Superoxide Dismutase (SOD) Enzyme on Frailty and Health Related Quality of Life Among Indonesian Pre-frail Elderly: A Double Blind Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2016
Overall Recruitment Status
Unknown status
Study Start Date
April 2016 (undefined)
Primary Completion Date
February 2017 (Anticipated)
Study Completion Date
April 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indonesia University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective is to determine the effect of SOD enzyme on frailty and health related quality of life among Indonesian pre-frail elderly. The secondary objective is to determine the effect of SOD enzyme on anti-oxidant status, morbidity, and hospitalization among Indonesian pre-frail elderly. The study hypothesis: SOD enzyme can improve frailty status and health related quality of life among Indonesian pre-frail elderly. SOD enzyme can increase anti-oxidant serum status among Indonesian pre-frail elderly. SOD enzyme can decrease morbidity among Indonesian pre-frail elderly. SOD enzyme can decrease hospitalization events among Indonesian pre-frail elderly.
Detailed Description
Study design: randomized double blind placebo controlled trial. Location and time of study: Geriatric Outpatient Clinic and Internal Medicine Outpatient Clinic in Cipto Mangunkusumo National Hospital Jakarta. Study will be conducted on April 2016 to April 2017. Study subject: elderly outpatient (aged 60 years old or more) with pre-frail status, who visit the clinic for medical consultation. Data sampling: consecutive method. Sample size: 150 subjects (75 control group, 75 intervention group). Data collection: demographic data, frailty status, health related quality of life, anthropometric data, anti-oxidant serum status, hospitalization during intervention, morbidity, nutritional status, food intake, hand grip strength. Intervention: SOD+Gliadin in capsule with a dose of 250 mg twice a day for 24 weeks will be given to intervention group, while placebo group will be given placebo capsule (amylum).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pre-frail Elderly
Keywords
Elderly, pre-frail, SOD

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Active Comparator
Arm Description
SOD+Gliadin capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
SOD+Gliadin Capsule
Other Intervention Name(s)
GLISODin
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Frailty status
Description
Measured by FI-40 item questionnaire.
Time Frame
6 months (24 weeks)
Secondary Outcome Measure Information:
Title
Health related quality of life
Description
Measured by EQ5D questionnaire.
Time Frame
6 months (24 weeks)
Title
Anti-oxidant serum status
Description
Measured by erythrocyte antioxidant enzymes activity, i.e. superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX).
Time Frame
6 months (24 weeks)
Title
Morbidity
Description
Measured by Cumulative Illness Rating Score (CIRS).
Time Frame
6 months (24 weeks)
Title
Hospitalization
Description
Observed hospitalization event during the study
Time Frame
6 months (24 weeks)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Elderly aged 60 years or more with pre-frail condition Patients with SOD enzyme deficiency Willing to participate Exclusion Criteria: Patients with cognitive function impairment (AMT score < 8) Patients with depression (Geriatric depression scale score >= 10) Patients with history of cirrhotic hepatic disease or severe hepatic disease Patients with kidney function impairment Patients with gluten allergy and derivative products Patients consume other antioxidant and omega-3 supplement
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Siti Setiati, Prof, MD, PhD
Phone
8138985588
Ext
+62
Email
s_setiati@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
Purwita Wijaya Laksmi, MD
Phone
8161390993
Ext
+62
Email
pwlaksmi@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Siti Setiati, Prof, MD, PhD
Organizational Affiliation
Fakultas Kedokteran Universitas Indonesia
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Purwita Wijaya Laksmi, MD
Organizational Affiliation
Fakultas Kedokteran Universitas Indonesia
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Kuntjoro Harimurti, MD
Organizational Affiliation
Fakultas Kedokteran Universitas Indonesia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rahmi Istanti, MARS
Organizational Affiliation
Fakultas Kedokteran Universitas Indonesia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cipto Mangunkusumo National Hospital
City
Jakarta
ZIP/Postal Code
10430
Country
Indonesia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rahmi Istanti, MARS
Phone
8151974578
Ext
+62
Email
r_istanti@hotmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
23245606
Citation
Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD, Murray CJ. Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2144-62. doi: 10.1016/S0140-6736(12)61690-0. Erratum In: Lancet. 2013 Feb 23;381(9867):628.
Results Reference
background
PubMed Identifier
25468154
Citation
Rodriguez-Manas L, Fried LP. Frailty in the clinical scenario. Lancet. 2015 Feb 14;385(9968):e7-e9. doi: 10.1016/S0140-6736(14)61595-6. Epub 2014 Nov 6. No abstract available.
Results Reference
background
PubMed Identifier
23395245
Citation
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013 Mar 2;381(9868):752-62. doi: 10.1016/S0140-6736(12)62167-9. Epub 2013 Feb 8. Erratum In: Lancet. 2013 Oct 19;382(9901):1328.
Results Reference
background
PubMed Identifier
25348178
Citation
Laksmi PW. Frailty syndrome: an emerging geriatric syndrome calling for its potential intervention. Acta Med Indones. 2014 Jul;46(3):173-4. No abstract available.
Results Reference
background
PubMed Identifier
24448330
Citation
Setiati S, Harimurti K, Dewiasty E, Istanti R, Mupangati YM, Ngestiningsih D, Purwoko Y, Aryana IS, Kuswardhani RT, Pramantara ID, Apandi M, Dwipa L, Budiningsih F, Dinda R, Widajanti N, Siburian P, Sunarti S, Umar S, Jim E, Junaidi-Ar. Profile of food and nutrient intake among Indonesian elderly population and factors associated with energy intake: a multi-centre study. Acta Med Indones. 2013 Oct;45(4):265-74.
Results Reference
background
PubMed Identifier
19054885
Citation
Setiati S. Vitamin D status among Indonesian elderly women living in institutionalized care units. Acta Med Indones. 2008 Apr;40(2):78-83.
Results Reference
background
PubMed Identifier
16505261
Citation
Gill TM, Gahbauer EA, Allore HG, Han L. Transitions between frailty states among community-living older persons. Arch Intern Med. 2006 Feb 27;166(4):418-23. doi: 10.1001/archinte.166.4.418.
Results Reference
background
PubMed Identifier
25348180
Citation
Sumantri S, Setiati S, Purnamasari D, Dewiasty E. Relationship between metformin and frailty syndrome in elderly people with type 2 diabetes. Acta Med Indones. 2014 Jul;46(3):183-8.
Results Reference
background
PubMed Identifier
25506599
Citation
Wang CP, Lorenzo C, Espinoza SE. Frailty Attenuates the Impact of Metformin on Reducing Mortality in Older Adults with Type 2 Diabetes. J Endocrinol Diabetes Obes. 2014;2(2):1031.
Results Reference
background
PubMed Identifier
25389961
Citation
Kobayashi S, Asakura K, Suga H, Sasaki S; Three-generation Study of Women on Diets and Health Study Groups. Inverse association between dietary habits with high total antioxidant capacity and prevalence of frailty among elderly Japanese women: a multicenter cross-sectional study. J Nutr Health Aging. 2014 Nov;18(9):827-39. doi: 10.1007/s12603-014-0478-4.
Results Reference
background
PubMed Identifier
17441415
Citation
Cloarec M, Caillard P, Provost JC, Dever JM, Elbeze Y, Zamaria N. GliSODin, a vegetal sod with gliadin, as preventative agent vs. atherosclerosis, as confirmed with carotid ultrasound-B imaging. Eur Ann Allergy Clin Immunol. 2007 Feb;39(2):45-50.
Results Reference
background
PubMed Identifier
18299493
Citation
Ensrud KE, Ewing SK, Taylor BC, Fink HA, Cawthon PM, Stone KL, Hillier TA, Cauley JA, Hochberg MC, Rodondi N, Tracy JK, Cummings SR. Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med. 2008 Feb 25;168(4):382-9. doi: 10.1001/archinternmed.2007.113.
Results Reference
background
PubMed Identifier
24804252
Citation
Peng C, Wang X, Chen J, Jiao R, Wang L, Li YM, Zuo Y, Liu Y, Lei L, Ma KY, Huang Y, Chen ZY. Biology of ageing and role of dietary antioxidants. Biomed Res Int. 2014;2014:831841. doi: 10.1155/2014/831841. Epub 2014 Apr 3.
Results Reference
background
PubMed Identifier
24040282
Citation
Bjelakovic G, Nikolova D, Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? PLoS One. 2013 Sep 6;8(9):e74558. doi: 10.1371/journal.pone.0074558. eCollection 2013.
Results Reference
background
PubMed Identifier
24669288
Citation
Persson T, Popescu BO, Cedazo-Minguez A. Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail? Oxid Med Cell Longev. 2014;2014:427318. doi: 10.1155/2014/427318. Epub 2014 Jan 5.
Results Reference
background
PubMed Identifier
19465742
Citation
Flores-Mateo G, Carrillo-Santisteve P, Elosua R, Guallar E, Marrugat J, Bleys J, Covas MI. Antioxidant enzyme activity and coronary heart disease: meta-analyses of observational studies. Am J Epidemiol. 2009 Jul 15;170(2):135-47. doi: 10.1093/aje/kwp112. Epub 2009 May 22.
Results Reference
background
PubMed Identifier
24079768
Citation
Laosa O, Alonso C, Castro M, Rodriguez-Manas L. Pharmaceutical interventions for frailty and sarcopenia. Curr Pharm Des. 2014;20(18):3068-82. doi: 10.2174/13816128113196660705.
Results Reference
background

Learn more about this trial

The Effect of SOD Enzyme on Frailty and HRQOL Among Indonesian Pre-frail Elderly: A Double Blind Randomized Controlled Trial

We'll reach out to this number within 24 hrs